Showing results (2421-2430 of 2,541) with videos related to

Sort By:
Pageof 255
Current Biology : CB|November 10, 2015
Cyp27c1 Red-Shifts the Spectral Sensitivity of Photoreceptors by Converting Vitamin A1 into A2Jennifer M Enright, Matthew B Toomey, Shin-ya Sato, et al.
JAMA Network Open|January 16, 2019
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical TrialAlan E Jones, Michael A Puskarich, Nathan I Shapiro, et al.
Blood|June 16, 2011
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsSimone M Schoenwaelder, Kate E Jarman, Elizabeth E Gardiner, et al.
The Journal of Experimental Medicine|May 27, 2015
Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1βMan Lyang Kim, Jae Jin Chae, Yong Hwan Park, et al.
Journal of Neuroinflammation|October 25, 2008
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infectionGretchen Hermes, James W Ajioka, Krystyna A Kelly, et al.
Leukemia|July 29, 2017
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1T-C Teh, N-Y Nguyen, D M Moujalled, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1Ben A Croker, Joanne A O'Donnell, Cameron J Nowell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseAndrew W Roberts, John F Seymour, Jennifer R Brown, et al.
BMJ Open|January 29, 2018
Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of NamibiaOliver F Medzihradsky, Immo Kleinschmidt, Davis Mumbengegwi, et al.
Pageof 255